Strategic shift Vyaire Medical is no longer actively trading as a standalone entity and has sold its respiratory diagnostics unit to Trudell Medical, rebranding as Jaeger. This presents an opportunity to pursue legacy customers and distribution channels through Jaeger and its global footprint.

Acquisition opportunity The RDx respiratory diagnostics unit was sold to Trudell Medical, indicating a continued demand for Jaeger-branded pulmonary function and cardio-pulmonary testing solutions. Target customers who previously engaged with Vyaire RDx may be up for replacement or new sourcing via Jaeger.

Bankruptcy context Chapter 11 proceedings and asset divestitures suggest potential for distressed or stable buyers in related segments. There may be acquiring interest from competitors or suppliers looking to expand portfolio, creating cross-sell or win-back potential with service contracts, consumables, and support.

Financial footprint Revenue is estimated between 50 and 100 million with a workforce of 501–1000, indicating mid-market scale. This size supports mid-tier sales motions for hardware, consumables, and service offerings to hospitals and clinics seeking reliable, scalable pulmonary testing solutions.

Market positioning Jaeger remains active globally in pulmonary function and cardio-pulmonary testing. Opportunities exist to align with customers needing integrated hardware, consumables, and services, including respiratory diagnostics, airways, and anesthesia-related products, through cross-sell with Jaeger’s extended portfolio.